The proven Zacks Rank system focuses on earnings estimates and estimate revisions to find winning stocks. Nevertheless, we know that our readers all have their own perspectives, so we are always looking at the latest trends in value, growth, and momentum to find strong picks. Looking at the history of these trends, perhaps none is more beloved than value investing. This strategy simply looks to identify companies that are being undervalued by the broader market. Value investors use tried-and-true metrics an ...

Collegium Pharmaceutical, Inc. (NASDAQ:COLL) Q2 2024 Earnings Conference Call August 8, 2024 4:30 PM ET Company Participants Christopher James - Vice President of Investor Relations Mike Heffernan - Interim President and Chief Executive Officer, Founder & Chairman Colleen Tupper - Chief Financial Officer Scott Dreyer - Chief Commercial Officer Conference Call Participants David Amsellem - Piper Sandler Les Sulewski - Truist Securities Operator Greetings, and welcome to the Collegium Pharmaceutical Second Qu ...

Q2'24 Earnings Report ✈Collegium. PHARMACEUTICAL August 8, 2024 | Nasdaq: COLL Forward-Looking Statements 2 This presentation contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. We may, in some cases, use terms such as "predicts," "forecasts," "believes," "potential," "proposed," "continue," "estimates," "anticipates," "expects," "plans," "intends," "may," "could," "might," "should" or other words that convey uncertainty of future events or outcome ...

Collegium Pharmaceutical (COLL) reported $145.28 million in revenue for the quarter ended June 2024, representing a year-over-year increase of 7.2%. EPS of $1.62 for the same period compares to $1.26 a year ago. The reported revenue represents a surprise of +1.08% over the Zacks Consensus Estimate of $143.73 million. With the consensus EPS estimate being $1.56, the EPS surprise was +3.85%. While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compar ...

Collegium Pharmaceutical (COLL) came out with quarterly earnings of $1.62 per share, beating the Zacks Consensus Estimate of $1.56 per share. This compares to earnings of $1.26 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of 3.85%. A quarter ago, it was expected that this specialty pharmaceutical company would post earnings of $1.49 per share when it actually produced earnings of $1.45, delivering a surprise of -2.68%. Over t ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-37372 Collegium Pharmaceutical, Inc. (Exact name of registrant as specified in its charter) Virginia (State or ...

Exhibit 99.1 Collegium Reports Second Quarter 2024 Financial Results – Generated Q2'24 Net Revenue of $145.3 Million and Record Belbuca® Revenue of $52.2 Million, Up 7% and 21% Year-over-Year, Respectively – – Achieved Q2'24 GAAP Net Income of $19.6 Million, Up 51% Year-over-Year – – Delivered Q2'24 Adjusted EBITDA of $96.0 Million, Up 12% Year-over-Year – – On Track to Close Acquisition of Ironshore Therapeutics in Q3'24, Adding Commercial Product Jornay PM® to Portfolio and Establishing Presence in Neurol ...

In its upcoming report, Collegium Pharmaceutical (COLL) is predicted by Wall Street analysts to post quarterly earnings of $1.56 per share, reflecting an increase of 23.8% compared to the same period last year. Revenues are forecasted to be $143.73 million, representing a year-over-year increase of 6%. The consensus EPS estimate for the quarter has been revised 0.2% higher over the last 30 days to the current level. This reflects how the analysts covering the stock have collectively reevaluated their initia ...

Collegium Pharmaceutical (COLL) is expected to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended June 2024. This widely-known consensus outlook gives a good sense of the company's earnings picture, but how the actual results compare to these estimates is a powerful factor that could impact its near-term stock price. The stock might move higher if these key numbers top expectations in the upcoming earnings report, which is expected to be released o ...

Collegium Pharmaceutical (COLL) shares rallied 10.6% in the last trading session to close at $38.60. This move can be attributable to notable volume with a higher number of shares being traded than in a typical session. This compares to the stock's 7% gain over the past four weeks. This specialty pharmaceutical company is expected to post quarterly earnings of $1.45 per share in its upcoming report, which represents a year-over-year change of +15.1%. Revenues are expected to be $142.2 million, up 4.9% from ...